"Le CHL est l’établissement support du GHT. C’est l’hôpital le plus important du Pas-de-Calais en termes d’activité. Il propose, à quelques exceptions près, l’ensemble des spécialités médicales, chirurgicales et obstétricales. Il s’appuie sur un plateau technique conséquent et complet (imagerie, labo, blocs opératoires, consultations, ...), une maternité de niveau 3, et certaines activités généralement limitées aux CHU. Il dispose d’un service d’urgences à très forte activité et reconnu comme centre de recours sur le territoire dans plusieurs domaines."

During the past decade, CH de Lens conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH de Lens" #1 sponsor was "The Lymphoma Academic Research Organisation" with 5 trials, followed by "Celgene" with 2 trials sponsored, "Intergroupe Francophone du Myelome" with 2 trials sponsored, "ARCAGY/ GINECO GROUP" with 1 trials sponsored and "Biotronik France" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH de Lens" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Biotronik SE & Co. KG" with 1 trials as a collaborator, "CHU de Nancy" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "CH de Lens" are "Diffuse Large B-cell Lymphoma" (2 trials), "Multiple Myeloma" (2 trials), "Primary Myelofibrosis" (2 trials), "Acute Respiratory Failure" (1 trials) and "Anemia" (1 trials). Many other conditions were trialed in "CH de Lens" in a lesser frequency.

Most popular intervention types in "CH de Lens" are "Drug" (9 trials), "Other" (5 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (3 trials), "Lenalidomide" (2 trials), "1 year follow-up to assess psychiatric morbidity" (1 trials), "6 months follow-up to assess the prevalence of PTSD symptoms" (1 trials) and "Administration of the IPREA3 questionnaire" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH de Lens" are 16 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CH de Lens". 1 are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in CH de Lens, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in CH de Lens, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".